| Literature DB >> 32330411 |
Nathalie Escande-Beillard1, Abigail Loh2, Sahar N Saleem3, Kohei Kanata4, Yui Hashimoto5, Umut Altunoglu6, Artina Metoska7, Joanes Grandjean8, Fui Mee Ng9, Oz Pomp2, Nithya Baburajendran9, Joyner Wong9, Jeffrey Hill9, Emmanuel Beillard10, Patrick Cozzone8, Maha Zaki11, Hülya Kayserili6, Hiroshi Hamada4, Hidetaka Shiratori12, Bruno Reversade13.
Abstract
Patients lacking PYCR2, a mitochondrial enzyme that synthesizes proline, display postnatal degenerative microcephaly with hypomyelination. Here we report the crystal structure of the PYCR2 apo-enzyme and show that a novel germline p.Gly249Val mutation lies at the dimer interface and lowers its enzymatic activity. We find that knocking out Pycr2 in mice phenocopies the human disorder and depletes PYCR1 levels in neural lineages. In situ quantification of neurotransmitters in the brains of PYCR2 mutant mice and patients revealed a signature of encephalopathy driven by excessive cerebral glycine. Mechanistically, we demonstrate that loss of PYCR2 upregulates SHMT2, which is responsible for glycine synthesis. This hyperglycemia could be partially reversed by SHMT2 knockdown, which rescued the axonal beading and neurite lengths of cultured Pycr2 knockout neurons. Our findings identify the glycine metabolic pathway as a possible intervention point to alleviate the neurological symptoms of PYCR2-mutant patients.Entities:
Keywords: HLD10; MRS; PYCR1; PYCR2; SHMT2; cerebral glycine; hypomyelination; microcephaly; mouse models; neurodegeneration
Mesh:
Substances:
Year: 2020 PMID: 32330411 DOI: 10.1016/j.neuron.2020.03.028
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173